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ABSTRACT
Introduction: Individuals exposed to red blood cell
alloantigens through transfusion, pregnancy or
transplantation may produce antibodies against the
alloantigens. Alloantibodies can pose serious clinical
problems such as delayed haemolytic reactions and
logistic problems, for example, to obtain timely and
properly matched transfusion blood for patients in
which new alloantibodies are detected.
Objective: The authors hypothesise that the particular
clinical conditions (eg, used medication, concomitant
infection, cellular immunity) during which transfusions
are given may contribute to the risk of immunisation.
The aim of this research was to examine the
association between clinical, environmental and
genetic characteristics of the recipient of erythrocyte
transfusions and the risk against erythrocyte
alloimmunisation during that transfusion episode.
Methods and analysis
Study design: Incident caseecohort study.
Setting: Secondary care, nationwide study (within the
Netherlands) including seven hospitals, from January
2005 to December 2011.
Study population: Consecutive red cell transfused
patients at the study centres.
Inclusion: The study cohort comprises of consecutive
red blood cell transfused patients at the study centre.
Exclusion: Patients with transfusions before the study
period and/or pre-existing alloantibodies.Cases deﬁned
as ﬁrst time alloantibody formers; Controls deﬁned as
transfused individuals matched (on number of
transfusions) to cases and have not formed an
alloantibody.
Statistical analysis: Logistic regression models will
be used to assess the association between the risk to
develop antibodies and potential risk factors, adjusted
for other risk factors.
Ethics and dissemination: Approval at each local
ethics regulatory committee will be obtained. Data will
be coded for privacy reasons. Patients will be sent
a letter and an information brochure explaining the
purpose of the study. A consent form in presence of
the study coordinator will be signed before the blood
taking commences. Investigators will submit progress
summary of the study to study sponsor regularly.
Investigators will notify the accredited ethics board of
the end of the study within a period of 8 weeks.
INTRODUCTION
Individuals exposed to red blood cell (RBC)
alloantigens through transfusion, pregnancy
or transplantation may produce antibodies
against the alloantigens expressed by RBCs.
Although the incidence of these events is
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ARTICLE SUMMARY
Article focus
- Identifying transfusion-related risk factors of
alloimmunisation against red blood cell (RBC)
antigens.
- Identifying clinical risk factors of alloimmunisation
against RBC antigens.
- Identifying environmental and genetic risk
factors of alloimmunisation against RBC
antigens.
Key messages
- Alloimmunisation against RBC transfusion is
a clinically relevant problem faced by transfusion
specialists.
- Identifying a high-risk group of responders who
form allantibodies against transfused RBCs
would be the next step towards transfusion of
complete phenotyped matched RBC.
- In synergy with other ongoing studies, cost-
effectiveness of a phenotyped matched RBC
approach will be assessed.
Strengths and limitations of this study
- Multicentre, matched caseecohort design.
- Good representative sample of controls from
large base cohort of general population.
- Cases and controls matched on the number of
RBC transfusions.
- Possibility that patients entering cohort have had
transfusions prior to start of study period in
other hospitals/non-study centres.
- Previous pregnancies in women could play a role
in alloimmunisation. Retrospective data will not
allow for a comprehensive check on previous
pregnancies.
- There could be a few cases selected who are
booster/secondary alloimmune responders,
instead of ﬁrst time ever alloantibody formers.
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Open Access Protocoldebated and ranges between the percentages of 1%e6%
in single transfused and up to 30% in polytransfused
patients (eg, sickle cell disease, thalassaemia and
myelodysplasia),
1 they can pose serious clinical problems
such as delayed haemolytic reactions as well as logistic
problems, for example, to obtain timely and properly
matched transfusion blood for patients in which new
alloantibodies are detected. Of course, prevention of
alloimmunisation by extended matching between
donors and all transfused patients (ie, on the basis of
typing patients for the most relevant RBC antigens)
would be an ultimate but complicated and costly solu-
tion. However, matching of donors only for patients who
are deﬁned to have a high alloimmunisation risk would
be a more feasible step forward. This strategy would be
especially valuable because as soon as immunisation for
one antigen develops, additional immunisations tend to
develop more frequently.
23
Characterisation of patients and clinical conditions
with high immunisation risk can be derived from
studying the possible correlations between the actual
immunisation and patient-related factors (both genetic
and acquired) and/or transfusion-associated situations.
Such a study comparing immunised and non-immunised
patients with a similar transfusion history will generate RR
or relative protective factors.
We expect a twofold impact from our study: (1) to
identify a set of transfusion recipients who need to be
extensively matched and (2) to help understand the
mechanisms underlying the development of alloanti-
bodies to erythrocyte transfusion.
RATIONALE/BACKGROUND
Alloantibodies can lead to serious clinical consequences
and logistic problems like obtaining properly and timely
matched blood for the patients who do develop these
antibodies. Prevention of such serious events is possible
by extended matching and typing of donor’s blood
against the patient’s for all the possible antigens, but this
process is cumbersome and costly. Identifying a high-risk
group will be a feasible ﬁrst target and advanced
matching a big step forward, and the aim of our study.
It is known that the recipient’s formation of antibodies
depends not only on dose and route of administration
and the immunogenicity of the antigen but probably
also on genetic or acquired patient-related factors. It has
been shown that the number of transfusions also plays
an important role in alloimmunisation against RBC, with
the risk increasing with the increasing number of
transfusions.
4 It is generally recognised that immuno-
compromised patients have a lower risk to develop such
antibodies.
5 Relatively little is known, however, about
other patient-related risk factors.
236 e9
A recent study examined such patient-related risk
factors in a caseecontrol study among 101 cases devel-
oping erythrocyte alloantibodies and 87 controls.
10 In
this two-centre study, patients with ﬁrst time detected
antibodies and at least one transfusion in the past were
compared with controls with a negative antibody
screening in the same centre. After adjustment for
a limited number of confounders, this study conﬁrmed
known risk factors for antibody formation, such as female
sex (increased risk, since women are more susceptible to
exposure of alloantigens during pregnancy, miscarriages,
abortions and childbirth
11), lymphoproliferative disease
and leukaemia (lower risk attributed to lymphocyte
dysfunction by concomitant chemotherapy and suppres-
sion of the immune response
12). Also new and partly
unexpected risk factors were found, such as diabetes and
solid tumours (both increased risk). Although the latter
patients do undergo chemotherapy as well, in this group,
antibodies might develop more easily because of their
chronic inﬂammatory state.
13 The limitations of this
caseecontrol study,
10 however, were (1) the selection
method for controls favoured controls that had received
more transfusions with also smaller transfusion time
intervals compared with the cases, (2) the relatively small
number of patients reducing the detection of smaller RRs
and (3) a relatively crude assessment of only a limited
number of potential risk factors. Additionally, the study
design did not allow investigating the association with the
actual factors at the time of the likely primary immuni-
sation/causal transfusion. We will not only try to conﬁrm
the observed potential risk factors in a larger cohort, but
we aim to ﬁnd other clinical, environmental as well as
genetic factors. There is well-documented evidence that
certain human leukocyte antigen (HLA) types are asso-
ciated with enhanced response to RBC antigens like Kell,
Duffy and Kidd.
14e16 HLA genes in this respect are
particularly interesting because along with their poly-
morphisms, they have been shown to play an active role
in autoimmune disorders and diseases, which develop via
T cell-mediated immunity.
17 Moreover, several of these
genes have been identiﬁed in human studies to be asso-
ciated with susceptibility and resistance to mycobacterial
infection. Another strong correlation was shown between
immunodeﬁcient genotype (interferon g receptor 1
deﬁciency) and responsiveness to mycobacterium
antigen.
18 Finally, speciﬁc single nucleotide poly-
morphism (SNP) associations have been identiﬁed to
play a role in viral immunity and variations in both
humeral and cellular immunity following measles vacci-
nation.
19 20 Although many genes are involved in the
immune system, SNP’s in genes (eg, coding for HLA
types) that modulate speciﬁc and innate immune
responses will be of the ﬁrst targets in our analyses. We
hypothesise that this will yield genetic modulators on the
patients’ humoural response to particular erythrocyte-
expressed antigens but maybe even more broadly to
other antigens as well.
By our questionnaire, we will query environmental,
lifestyle factors and socioeconomic status as those have
been suggested to modulate the immune response.
Environmental factors such as exposure to helminthic,
fungal and parasitic infections do play a role in modu-
lating the general set point of the immune response at
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R-FACT Studyyoung age.
21 The same is true for living in unsanitary
conditions and for unhygienic occupations throughout
life.
22 Additional information on ‘immune modulating’
conditions during childhood and youth will be collected
from the vaccination status, completion of the vaccina-
tion programme, presence of pet animals, place of resi-
dence (urban/rural) and visits to day care centres
during childhood. The questionnaire will add to the
knowledge to these possible confounders in cases and
controls.
RESEARCH OBJECTIVE
The aim of the project was to examine the association
between clinical, environmental and genetic character-
istics of the recipient of erythrocyte transfusions and the
risk of immunisation against erythrocyte alloantigens
that he/she was exposed to during that transfusion
episode.
METHODOLOGY
Study design and study population
We will perform a retrospective matched caseecohort
study at hospitals nationwide from a period January 2005
to December 2011. Large RBC using hospitals will be
selected as study bases. The study cohort will comprise of
consecutive RBC transfused patients at the study centre.
Cases are deﬁned as ﬁrst time ever irregular RBC
antibody formers, with no history of RBC transfusions
and alloimmunisation before the study period.
Controls will be all consecutive transfused patients
who had received their ﬁrst and subsequent red blood
transfusions at the study centre with no history of RBC
transfusions and alloimmunisation.
Observational studies, if well conducted, are equipped
to examine interesting transfusion research questions.
With that in mind, we chose a caseecohort study design
for our study. With the help of such a design, we can
compare the cases occurring in a RBC transfused cohort
with a randomly selected sample of the cohort. Using
such an approach, for any one given case, we will select
two controls that have had at least the same number or
more transfusions than the case itself. This approach has
following advantages:
1. This ensures that all the patients in the transfusion
cohort with same or higher number of transfusions
have an equal chance of being picked as controls. In
essence, any member of the cohort who has been at
a similar transfusion risk (of alloimmunisation) at
some point in their transfusion history can be
selected as a control.
2. Cases also have an equal chance of getting selected as
controls for other cases.
This study design minimises the selection bias, if any.
Such a study design allows us to include a number of
patients, which is sufﬁcient to detect smaller effects and
to adjust for other risk factors, as well as to document
potential risk factors extensively.
Matching
We will take into account the number of transfusions
a particular case received until the antibody-forming
episode and match the two cases (selected per control)
on the same number of transfusions.
To account for interhospital differences nationwide,
we will also match the cases and controls on the site/
study centre (ﬁgure 1).
Implicated period
To examine the immunomodulating clinical risk factors
surrounding the transfusions preceding the date of
alloantibody formation, we will deﬁne a clinical risk period
or an implicated period of alloimmunisation during which
the case would have formed an irregular RBC antibody.
This period would be the time (in days) between the
date of a ﬁrst ever positive screen for alloantibody to
a calendar date 30 days before that positive screen. We
will also introduce a lag period of minimum 7 days
between that ﬁrst ever positive screen and the last ever
transfusion (implicating transfusion) before that positive
screen (ﬁgure 2). This is to ensure that a patient’s
immune system has adequate time to respond to the
transfusion exposure.
We will deﬁne a similar implicated period in the
matched controls as well, retrospectively from the impli-
cating transfusion to 30 calendar days back (ﬁgure 2).
First time formed alloantibody
Our endpoint for cases, or ﬁrst time formed irregular
RBC antibodies is deﬁned as clinically signiﬁcant anti-
bodies as screened by a three-cell serology panel at 378C.
All patients were routinely screened for alloantibodies,
Figure 1 Flowchart of study design for the matched control
group.
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R-FACT Studywhich is repeated at least every 72 h, if further trans-
fusions as required. The antibodies are screened for by
a three-cell panel, including an indirect antiglobulin test
(LISS Diamed ID gel system, DiaMed-ID system, DiaMed,
Murten, Switzerland) and subsequently identiﬁes by
a standard 11 cell panels in the same gel system.
Data acquirement, measurements and handling
Transfusion cohort data will be acquired from the
hospital blood transfusion services and on-site patient
records. Second, we will use data from a patient ques-
tionnaire. Third, we will determine the patients’ racial
background from blood of the included and consenting
patients.
Patient medical history and records
Potential clinical risk factors include haematological,
oncological, surgical and medicinal data as well as
autoimmune diseases and related conditions at the time
of the implicated (likely causal) transfusion. Factors and
conditions that will be actively scored are: infections
(including the causal microorganisms) and active/
chronic allergies (including the if known antigens),
fever, cytopenia(s), systemic inﬂammatory response
(a clinical response to a (non)-speciﬁc insult of either
infectious or non-infectious origin), peripheral blood
progenitor cells transplantation (autologous or alloge-
nous), multitrauma, splenectomy, solid malignancies,
autoimmune disorders (rheumatoid arthritis, diabetes
mellitus type 1, etc), chemotherapy, immunosuppressive
drugs, cytostatics and antibiotics will be studied.
Questionnaire
Participants will be asked to ﬁll out a printed question-
naire. The participants have also the option to ﬁll in
a web-based questionnaire, which will be accessible via
a link provided in the information letter. After identiﬁ-
cation of control patients, a similar mailing will be sent
to these controls.
Environmental and lifestyle factors like vaccination
status, previous pregnancies in case of females, level of
education and current professions (as a proxy for
socioeconomic status) will be obtained via the patient
information questionnaire. The questionnaire will add
to the knowledge to these possible confounders in cases
and controls.
In general, many questions will involve ‘life-time’ risk
factors and information and are not particularly targeted
at the time of implicated episode.
Racial confounder
Based on the knowledge that different ethnicities have
varying frequencies of erythrocyte antigens, a so-called
mismatch between a donor from one particular ethnicity
and the recipient of another ethnicity does play a role in
developing immune response to donor erythrocytes.
Therefore, we will also attempt to document racial
mismatch leading to RBC alloimmunisation. This is
attempted by one question in the questionnaire but will
foremost rely on the blood group typing, which usually
determines the ethnicity.
Blood research and sampling
To investigate the effect of genetic factors on the risk of
the development of alloantibodies, we will collect blood
samples from all participants for extensively typing the
blood to get an antigen proﬁle and to look at genetic
markers, which inﬂuence immune system and vaccina-
tion efﬁciency. SNP’s in candidate genes (eg, coding for
HLA types) modulating speciﬁc and innate immune
responses will be assessed. Biomarkers typical for the
activity of the immune response: cytokines and titres of
antibodies against common (vaccinated) antigens can
later be determined in the plasma and serum that are
stored as well.
Statistical analysis
We expect to include a total of 500 case patients and
1000 controls.
Logistic regression models will be used to assess the
association between the risk to develop antibodies and
Figure 2 Implicating period of clinical data collection.
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R-FACT Studypotential risk factors, adjusted for other risk factors and
for the number of exposures to the antigen.
We will examine the association between the risk factor
and alloimmunisation using logistic regression.
We will also make a selection of all cases and controls
on the most frequently found antibodies and if the
relative impact of risk factors and immune modulators
on the risk of all the antibody types (in separate analysis)
is in the same direction, we will make a generalised
observation.
With 1500 patients, and the conventional 80% power
and a p value of 0.05, we will be able to detect effects
(OR) of dichotomised risk factors of 1.35 or higher.
An additional analysis will be performed along the
lines of a ‘case-crossover’ design within the case patients.
The ‘Hazard Period’ (time period right before the
detection of a positive antibody) will be compared to
a ‘Control Component’ (a speciﬁed time period other
than the Hazard Period) in the case patient’s medical
history and the RR for the transient effect risk factors will
be calculated.
ETHICAL CONSIDERATIONS
Regulation statement
The study will have a multicentre design subjecting
patients to a questionnaire and additional blood
sampling. After approval by the central Medical Ethical
Committee (MEC) of the Leiden University Medical
Center (LUMC), the study clearly requires a local
Medical Ethical Committee approval for each site that
detects a probable transfusion-mediated alloimmunisa-
tion. Help of local investigators, usually the local
haematologist or clinical chemist in charge of the trans-
fusion laboratory, will be recruited to substantiate
implementation of the study at the various sites. Each
local investigator will in fact be responsible for ensuring
that the study will be conducted in his centre in accor-
dance with the protocol, the ethical principal of the
Declaration of Helsinki, current International Confer-
ence on Harmonization (ICH) guidelines on Good
Clinical Practice and applicable regulatory requirements.
Recruitment and consent
Data will be collected at each hospital site, Sanquin and
from medical records and ﬁles. All data will be coded for
privacy reasons. As said, after identiﬁcation of cases and
controls, patients will be sent a short and concise letter
and an information brochure explaining the purpose of
the study. This letter will be combined with the ques-
tionnaire and foremostdan answer card expressing
willingness or refusal to participate in the study to ﬁll in
and return to the study’s contact address. Participants,
moreover, will have an option of ﬁlling in the question-
naire via the study’s website. The web link access will be
explained in the patient information. After receiving
a patient’s positive response to our request to partici-
pate, a follow-up call will be made by the investigator to
answer any additional queries and if applicable to make
an appointment for the blood taking. The patients
would be invited to LUMC or the participating centres
for blood taking. Additionally to the signed answer card
for blood taking, patients would be informed about the
study once again at the blood taking appointment, and
a ﬁnal consent form in presence of the study coordinator
and data manager will be signed before the blood taking
commences. Proper tubing and transfer material will be
provided to the non-LUMC sites.
The patient burden
The reading of the information and completing the
questionnaire (estimated to take about 10 min) will be of
minimal patient burden or stress and is absolutely
voluntary. Apart from the questionnaire, the protocol
involves a single blood sampling of 25 ml as main
discomfort for cases and controls. However, the blood
taking will preferably be combined with a regular control
and if possible a blood sampling.
The blood taking will be organised centrally at the
LUMC upon invitations. There are no further interven-
tions within the study protocol. The study has absolute
minimum invasive risk for the patients.
Medical information, data and sample handling and reports
1. Per patient an electronic Case Record Form (CRF)
with a unique study number (identiﬁer) will be made.
The CRFs will be subjected to independent data
management. The principal investigators, Anske van
der Bom and J J Zwaginga, will be responsible for the
CRF and data management.
2. Patient-identifying parameters such as name, the
hospital patient number and the full birth date will
not be entered and found in the electronic CRF. The
key between these identifying data and the unique
study number will be only available to the data
management at the Department of Epidemiology.
These patient-identifying parameters are only needed
for sending the questionnaire and making an
appointment for blood taking, which will be done
by the data management. The blood taking and
further sampling will involve relabelling of the tubes
to the speciﬁc study number.
There will be a provision to keep the patient personal
details for the entire duration of storage of blood
samples, with a possibility to track back and identify the
patients with their blood samples. Coding measure will
ensure that this information is not available to a third
party and is only accessible via an encoding key to the
principal investigators of the R-FACT study. Individual
medical and investigational information obtained
during the study is considered conﬁdential and disclo-
sure to third parties is prohibited. The described strategy
will guarantee effective study of data together with
maintaining optimal patient privacy.
The blood samples will be stored in state-of-the-art
storage facilities at the LUMC, with storage management
software for 20 years.
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R-FACT StudyThe research, patient information, blood sampling
and storage will be conducted in accordance with
LUMC’s Good Research Practice guidelines.
Withdrawal of individuals
Subjects can decide to have their samples removed from
the serum, plasma, DNA and RNA bank and thus from
further research in the future at any time and for any
reason, that is, meaning without consequences for their
further clinical treatment.
Independent physician
Before consenting, patients can gather information or
advice from the investigator and also from an indepen-
dent physician. This name will be provided in the patient
information.
Objection by minors or incapacitated subjects
Not applicable.
Group-related risk assessment and beneﬁts
Not applicable.
Incentives
Not applicable.
ADMINISTRATIVE ASPECTS AND PUBLICATION
Handling and storage of data and documents
Data handling will comply with the Dutch Personal Data
Protection Act.
A data manager (employed on the project) and the
PhD fellow will extract data from the study sites and
recode patients and locations to unique study codes
under which non-patient identifying data are ﬁled in
a CRF per patient.
There will be no speciﬁc physical CRFs because of the
massive patient/control numbers and electronic data
sets can be often automatically extracted from the
patient information systems present in most hospitals.
Amendments
All amendments will be notiﬁed to the MEC that gave
a favourable opinion.
Annual progress report
The investigators will submit a progress summary of the
study to Sanquin as sponsor of the study regularly.
Information on inclusion of cases and controls, other
problems and amendments will be provided as required
by the regional and local MEC’s.
End of the study report
The investigator will notify the accredited MECs of the
end of the study within a period of 8 weeks. The end of
the study is deﬁned as the last data collected from
medical records and caseecontrol questionnaires.
Public disclosure and publication policy
The ﬁnal publication of the study results will be written
by the study coordinator(s) on the basis of the statistical
analysis performed. A draft manuscript will be submitted
to all co-authors for review. After revision, the manu-
script will be sent to a peer-reviewed scientiﬁc journal.
Any publication, abstract or presentation based on
patients included in the study must be approved by the
study investigators and collaborators.
EXPECTED RESULTS
Our caseecohort study will quantify and characterise
risks of patients and conditions for transfusion-associated
alloimmunisation, although a prospective serology study
involving a ﬁrst transfused cohort would be most prefer-
able to add to the insight in primary immunisation (risk).
However, 50% of ﬁrst transfused patients never need new
blood again and escape follow-up if not recalled. More-
over, the occurrence for the other 50% of the following
transfusion period is quite variable. Therefore,
a prospective study is viewed as cumbersome. On the
more practical side for a caseecontrol study, 50% of the
transfused patients have been transfused before and
these in principle are eligible as case or control patients.
Indeed, in accordance by the rules for inclusion, these
patients are already transfused at two different periods at
least. Therefore, if we can deﬁne risk factors for alloim-
munisation, then advanced matching of blood donors for
this group should be regarded as valuable. Finally, strong
synergy will be obtained between our study and the
MATCH study by Schonewille et al. In the latter study,
logistical/cost/and beneﬁt aspects of advanced matching
after formation of a ﬁrst antibody will be determined.
Our study will contribute to classifying patients who
could beneﬁt from additional or extended typing and
donor matching to prevent alloimmunisation. We envision
to contribute to a matching policy based on a prognostic
risk score for immunisation in general transfused patients.
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